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Feasibility and patient acceptability 
of a novel artificial intelligence-
based screening model for diabetic 
retinopathy at endocrinology 
outpatient services: a pilot study
Stuart Keel1, Pei Ying Lee1, Jane Scheetz1, Zhixi Li2, Mark A. Kotowicz3,4,5,  
Richard J. MacIsaac6,7 & Mingguang He  1,2
The purpose of this study is to evaluate the feasibility and patient acceptability of a novel artificial 
intelligence (AI)-based diabetic retinopathy (DR) screening model within endocrinology outpatient 
settings. Adults with diabetes were recruited from two urban endocrinology outpatient clinics and 
single-field, non-mydriatic fundus photographs were taken and graded for referable DR ( ≥ pre-
proliferative DR). Each participant underwent; (1) automated screening model; where a deep 
learning algorithm (DLA) provided real-time reporting of results; and (2) manual model where retinal 
images were transferred to a retinal grading centre and manual grading outcomes were distributed 
to the patient within 2 weeks of assessment. Participants completed a questionnaire on the day of 
examination and 1-month following assessment to determine overall satisfaction and the preferred 
model of care. In total, 96 participants were screened for DR and the mean assessment time for 
automated screening was 6.9 minutes. Ninety-six percent of participants reported that they were either 
satisfied or very satisfied with the automated screening model and 78% reported that they preferred 
the automated model over manual. The sensitivity and specificity of the DLA for correct referral was 
92.3% and 93.7%, respectively. AI-based DR screening in endocrinology outpatient settings appears to 
be feasible and well accepted by patients.
Diabetic retinopathy (DR), the most common microvascular complication of diabetes, is a leading cause of irre-
versible vision loss in Australian adults of working age1. With the prevalence of diabetes predicted to increase 
substantially in the coming decades2,3, a significant increase in the health impact and economic burden of DR is 
expected in Australia4.
It is estimated that 98% of vision loss from DR is avoidable through early detection and treatment strate-
gies5,6. As such, screening for DR has long been endorsed by the National Health and Medical Research Council 
(NHMRC), that recommend biennial screening for Australians without significant risk factors for retinopathy 
(e.g. poor glycaemic control, blood pressure or blood lipid controls) and annual screening (at least) for individ-
uals who have had a diagnosis of DR7. Despite the growing evidence of the effectiveness of national screening 
programs worldwide8,9, comprehensive DR screening strategies have not been widely implemented in Australia, 
resulting in a suboptimal compliance with diabetic retinal examination guidelines10.
Medicare, a government funded health insurance system that provides free or subsidised health care services 
to the Australia population, has recently introduced a new initiative that supports non-eye care professionals to 
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perform screening for DR using retinal photography11. While retinal photography is an effective screening tool 
for DR, it is highly dependent on interpretation by clinical experts12, posing a significant challenge to this model. 
Over the past two decades, automated techniques for the assessment of DR, via electronic medical records13,14 
and feature extraction from color retinal images15,16, have been reported with variable accuracy. The recent emer-
gence of deep learning-based artificial intelligence grading of DR represents an advancement of artificial neural 
networks that permit improved accuracy of disease classification (sensitivity and specificity > 90%) from raw 
image data17,18. These systems offer the potential to enable non-eye health professionals to perform opportunistic 
screening for DR and to make referral recommendations without the need for eye specialists. Despite this, there 
is a paucity of data relating to the clinical adoption of these technologies.
In light of this, we propose a novel and innovative screening strategy, combining an AI-based automatic grad-
ing algorithm for the detection of DR with the accessibility of endocrinology clinics. The purpose of this pilot 
study was to evaluate the feasibility and patient acceptability of this opportunistic screening model in two public 
hospital endocrinology outpatient clinics.
Methods
Participants. Patients who attended two urban endocrinology departments (St Vincent’s Hospital, 
Melbourne & University Hospital Geelong, Barwon Health) for diabetes care between July 6th, 2017 and 
November 2nd, 2017 (equivalent of 13 clinic days) were invited to participate in this study if they were at least 18 
years of age. For all eligible persons, a response as to whether participants accepted or refused participation was 
recorded after clearly explaining the project objectives and rationale for the AI-based automated retinal screen-
ing. For those who declined, a reason for refusal was obtained. At each screening site, a convenience sample of 50 
eligible patients were recruited. Ethics approval was obtained from the St Vincent’s Hospital and Barwon Health 
(HREC-LNR/17/SVHM/39) Human Research Ethics Committee’s. Study procedures adhered to the tenets of the 
Declaration of Helsinki as revised in 2013 and participants provided written informed consent to participate.
Development of a deep learning algorithm for referrable DR. The deep learning algorithm was developed 
using 66,790 retinal photographs acquired from an online dataset (http://www.labelme.org, Guangzhou, China). 
Using a simple random sampling method, a total of 58,790 images were assigned to the training dataset and the 
remaining 8,000 images were held-out for internal cross-validation. Amongst the 58,790 images in the training 
dataset, 10,861 (18.5%) had referable DR and 13,736 (27.5%) had diabetic macular edema (DME). In the develop-
ment of this algorithm, 21 ophthalmologists, who achieved robust agreement (Kappa ≥ 0.70) with an experienced 
ophthalmologist on a test set of 180 retinal images, were recruited as graders. Retinal images were graded accord-
ing to the NHS diabetic eye screening guidelines that have been described in detail elsewhere19. Referable DR was 
defined as moderate non-proliferative DR (NPDR) or worse and/or diabetic macular edema (DME). Each image 
was randomly assigned to a single ophthalmologist for initial grading and, following this, sequentially assigned to 
individual graders until three consistent grading outcomes were achieved. The consensus grading outcome was 
assigned as the final, conclusive grading of each image.
The system included four deep learning models, all using inception-v3 architecture training from scratch with 
a mini-batch gradient descent size of 32 and Adam optimizer of a 0.002 learning rate20. This included networks 
for the (1) classification for referable DR, (2) classification of DME, (3) evaluation of image quality for DR, and 
(4) assessment of image quality and of the availability of macular region for DME. The model used in this study 
was version 20170520.
Protocol. All eligible and consenting participants underwent a general questionnaire to collect informa-
tion on sociodemographic factors, previous ocular history, general health and use of eye health care services. 
Presenting distance visual acuity was measured in each eye using a logMAR chart (Brien Holden Vision Institute, 
Australia) in well-lit room conditions. Participants wore their habitual distance correction. One standard, 
45-degree, non-stereoscopic colour retinal photograph (central-nasal field) was taken of each eye using a Digital 
Retinography System (DRS, CenterVue SpA, Italy). Each participant underwent; (1) automated screening model, 
where retinal photographs were uploaded to EyeGraderTM (Healgoo Interactive Medical Technology Co. Ltd, 
Guangzhou, China), an online platform that enables retinal photograph upload, automated grading and genera-
tion of a single-page grading report including referral recommendations that was delivered to the patient at the 
time of consultation; and (2) manual telemedicine model, where retinal images were transferred to a centralised 
retinal grading centre and manual grading outcomes were distributed to the patient within 2 weeks of baseline 
assessment. Figure 1 shows a flowchart of the testing protocol.
On the day of examination, participants completed a self-administered modified client satisfaction questionnaire 
(CSQ-8) to collect details on their overall satisfaction with the automated model of care and likelihood of using 
the screening service again. Participants were recontacted (via their preferred model) at 1-month following base-
line assessment to confirm whether they had accessed their manual grading report and determine their preferred 
model of care. If participants could not be contacted after 3 attempts, they were not interviewed. The impact of the 
automated screening model on clinic flow was assessed using the average time taken for each screening episode per 
participant. Participants were provided with a referral to an optometry service if (a) their presenting visual acuity 
was <6/12 (current Australian driving standard) in either eye; or (b) they had referable DR.
Statistical analysis. We calculated descriptive statistics of the characteristics of patients and the average 
time taken for the automated DR screening model. Continuous variables were presented as mean (SD) and cate-
gorical variables were presented as absolute (n) and relative frequencies (%). The performance of the deep learn-
ing algorithm was evaluated using the ophthalmologist assessment as the reference standard. Sensitivity and 
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specificity were the key outcome measures. All statistical analysis was performed using Stata version 11 software 
(College Station, Texas, USA).
Results
Feasibility and acceptability of automated DR screening. Over the 4-month study period, a total of 
128 participants were invited to participate, of whom, 96 (75%) agreed and were subsequently screened for DR. 
The reasons for which individuals declined to participate included that they had a recent eye test (16/32, 50%), 
they had an upcoming appointment with an eye-care professional (7/32, 22%), or that they were not interested 
(3/32, 9%). The remaining 6 (6/32, 19%) individuals did not disclose a reason for refusal. The mean age of the 96 
study participants was 44.26 +/− 16.56 years (range = 20–90 years), 57% (55/96) were male and the mean dura-
tion of diabetes was 18.2 +/− 13.5 years. Twenty-five percent (24/96) of participants indicated that they had not 
had an eye examination for diabetes in the preceding 12 months.
Of the total 96 participants, 93 (96.9%) had a retinal photograph in at least one eye that was gradable for 
referrable DR (gradable images in only one eye = 10.8%, 10/93) using the deep learning algorithm. Of the three 
participants with bilateral ungradable retinal photographs, two were a result of small pupil size and one was due 
to bilateral media opacities. In the manual screening model, a grade for referrable DR was obtained in at least 
one eye for all participants. The mean time for the automated screening model was 6.9 +/− 1.4 minutes. The 
sensitivity and specificity of the DLA for correct referral was 0.933, 92.3% and 93.7%, respectively. In total, 17 
participants received a referral from the automated screening model. Of these, 12 were true positive referrals 
Figure 1. Flowchart of testing protocol.
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(referable DR = 10; VA < 6/12 = 2), 5 were false positives due to a misclassification of mild NPDR. There was one 
false negative case that proved to be undetected stable proliferate DR with subthreshold panretinal laser scars on 
manual grading.
Ninety-six percent (92/96) of participants reported that they were either satisfied or very satisfied with the 
automated screening model. None of the four participants who were unsatified with automated screening spec-
ified a reason. Eighty-nine percent (85/96) stated that they would be likely or extremely likely to use the service 
again and 89% (85/96) reported that they would recommend the automated retinal screening system to a friend.
Participant follow-up. Only 57% (55/96) of participants were able to be contacted 1-month following base-
line assessment after 3 attempts by researchers. Of these, 6 (11%) participants had not accessed their manual 
screening report and 78% (43/55) reported that they preferred the automated model over the manual model. 
A small number of participants (n = 5) commented that the reason for preferring automated grading was the 
convenience of immediate reporting of results. Of the 12 participants who preferred manual screening, only 50% 
(6/12) disclosed a reason. All 6 respondents stated that ‘trust’ was the key reason for preferring manual profes-
sional grading over machine diagnosis.
Among the 5 participants who were misclassified, only 2 responded to the telephone interview (after 3 
attempts). Of these, one preferred the automated model and the other preferred the manual model. Due to the 
low response amongst these individuals at follow-up, we are unable to make any robust discussion on whether 
misclassification by the automated model impacted a participant’s decision to choose manual grading as their 
preferred screening method.
Discussion
This pilot study indicates that our AI-based DR screening model appears to be feasible, accurate and well accepted 
by patients attending endocrinology outpatient settings. Herein, we describe novel data of the clinical adoption 
of a deep-learning algorithm for the detection of referable DR within two Australian endocrinology outpatient 
clinics.
Diabetic retinopathy screening strategies have long been trialled in non-ophthalmic settings in Australia with 
modest success21,22. Typically, these models integrate retinal photography and a centralised retinal grading centre 
that require support by highly trained professionals and involve a delay in communicating screening results to 
patients. Drawbacks of the manual DR screening model were highlighted in this study, with over 40% of patients 
unable to be re-contacted after 3 attempts and an additional 11% not accessing their manual grading report. 
The automated screening model, on the other hand, offers a technology-driven screening solution that enables 
point-of-care reporting of results, thereby potentially addressing many issues associated with the delayed com-
munication of results including patient anxiety, documentation errors and difficulties re-contacting patients23.
Our finding that more than 10% of participants had referrable DR is higher than a recent population-based 
report24. In addition, one quarter of participants had not undertaken annual DR screening providing evidence 
that endocrinology outpatient clinics may offer an ideal setting to opportunistically capture individuals with 
referrable disease and those who do not routinely attend eye care services for routine examinations. The AI-based 
diagnostic assistive technology utilised in this study coupled with the recent introduction of Medicare items for 
non-eye health physicians to screen for DR11 offers the potential to build sustainable DR screening within endo-
crinology settings.
There are several findings from this pilot study that indicate that the AI-based DR screening in endocrinology 
outpatient settings appears to be feasible, including; (1) the software was successfully incorporated with a fully 
automated retinal camera that requires minimal operator training; (2) the mean time per automated screening 
episode was approximately seven minutes, fitting in well with the routine clinical workflow; and (3) only 3% of 
participants had ungradable retinal images as classified by the deep learning algorithm, providing evidence of 
reliable image analysis using non-mydriatic photography. Furthermore, the performance indicators (sensitivity 
and specificity) are substantially better than what screening guidelines would typically recommend (>80% sen-
sitivity and specificity)18. Despite this, given the small number of referrable cases in the present study, further 
validation in larger patient cohorts is warranted.
A key challenge to the clinical adoption of this AI-based technology relates to a mind-set shift in how patients 
entrust clinical care to machines. In this study, 96% of participants reported that they were either satisfied or 
very satisfied with the automated screening model and nearly 80% reported that they preferred the automated 
screening model over the manual model, suggesting a good degree of patient acceptability of the system. Further 
research investigating clinician and organisational stakeholder acceptance, experiences and perspectives is 
required in order to assist in designing a sustainable service delivery model.
The key strength of this study includes its prospective study design that provides some of the first evidence of 
the adoption of a deep-learning algorithm in a point-of-care DR screening model. A number of limitations must 
also be considered. First, there was a relatively small representation of referrable cases in the sample, which may 
have resulted in an unstable estimate of diagnostic accuracy. It should also be noted that contrast between retinal 
background and DR lesions varies considerably among ethnicities, and is therefore a source of potential error for 
automatic detection systems. Although not detailed in this report, our algorithm has been validated in four eth-
nic groups, including Chinese (AUC = 0.989), Malay (AUC = 0.962), Caucasian (AUC = 0.969) and Indigenous 
Australian (AUC = 0.937), each with distinct retinal pigmentation (data not shown). Second, given the primary 
objectives of this study were to assess technical feasibility and patient acceptability, all patients aged 18 years and 
over were invited to participate in this pilot study. This does not accurately simulate the real-world application of 
this model, where only those who have not undertaken an annual retinal exam would be screened. Third, at first 
glance, the decline rate of 25% is noteworthy. However, 72% (23/38) of those who declined reported having had a 
recent eye examination or an upcoming eye-care appointment and were therefore unlikely to have benefited from 
www.nature.com/scientificreports/
5SCiEnTifiC RePoRtS |  (2018) 8:4330  | DOI:10.1038/s41598-018-22612-2
this endocrinology-based DR screening. Lastly, we did not evaluate the economic effectiveness of the automated 
screening model, nor did we assess adherence to referral rates. We plan to address these limitations in a longer 
term, multi-centre study. Future research will also focus on adopting the automated screening model to general 
practitioner clinics. Given 85% of the Australian population visit this service at least once every 12 months25, they 
too can potentially serve as a venue for opportunistic screening of DR.
In summary, this AI-based DR model appears to be feasible and well accepted by patients attending two endo-
crinology outpatient settings. Further work to investigate the impact (i.e. adherence to referral, new DR detection 
rates) and cost effectiveness of this model is ongoing.
Data Availability. The datasets generated during and/or analysed during the current study may be available 
from the corresponding author on reasonable request.
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